| Publisher’s Note: Fierce Biotech will not publish Monday, May 26, in observance of Memorial Day. We’ll be back in your inbox on Tuesday. |
|
Discover how our oncology-focused clinical development solutions help you move from milestone to milestone with speed and precision. Let’s talk smarter trials. Request more information.
|
|
Today’s Big NewsMay 23, 2025 |
| By Nick Paul Taylor Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” |
|
|
|
By Nick Paul Taylor Genmab has shared the first data on rinatabart sesutecan in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair analysts to boost confidence in the program ahead of its move into phase 3. |
By Dave Muoio Misdiagnoses, vaccine safety reporting and drugmakers' "corporate capture" earned substantial ink in a hotly anticipated report from the White House's Make America Healthy Again Commission, chaired by Department of Health and Human Services Secretary Robert F. Kennedy Jr. |
Sponsored by Bridge Bank, a division of Western Alliance Bank, Member FDIC Here’s how experienced banking partnerships create value beyond traditional lending and why industry-specific expertise matters in navigating the complex life sciences landscape. |
By Noah Tong,Dave Muoio Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions in force imposed on federal agencies like the HHS were unconstitutional. |
Sponsored by AGC Biologics Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce delays, unplanned costs, and batch failures. |
By Gabrielle Masson Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have prompted the company and partner Taiho Oncology to pursue an accelerated approval. |
Sponsored by Ohio Discovery Corridor Cleveland Diagnostics redefines cancer detection with new technology developed at the Cleveland Clinic in the heart of the Ohio Discovery Corridor. |
By James Waldron Innate Pharma has produced long-term data showing that its anti-KIR3DL2 antibody has a “sustained effect” against two types of lymphoma. |
By Angus Liu Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders. |
By Kevin Dunleavy In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of CAN-2409 in localized prostate cancer. Five months later, Candel has unveiled more information from the study, bolstering the value of the first-in-class treatment. |
By Darren Incorvaia,Zoey Becker Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit. |
By Fraiser Kansteiner Sanofi has officially opened its swanky new offices in Morristown, New Jersey, where nearly 2,000 employees recently relocated. The drugmaker invested $130 million in the new facility, which features flexible workspaces, wellness rooms, a public-facing restaurant and “the largest outdoor terrace space" in the state. |
By Noah Tong The Congressional Budget Office correctly stated Trump's tax bill would force cuts to Medicare. Budget analysts are tempering concerns, as the relevant provision is expected to be waived as in prior years. |
By Angus Liu Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. The FDA has granted its first official approval to a blood-based Alzheimer's disease test in a potential boon to anti-amyloid drugs. Samsung Biologics plans to spin off its biosimilars business. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
